Insider Selling: Natera, Inc. (NASDAQ:NTRA) CFO Sells $139,171.74 in Stock

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 1,523 shares of the business’s stock in a transaction on Tuesday, April 23rd. The stock was sold at an average price of $91.38, for a total transaction of $139,171.74. Following the completion of the sale, the chief financial officer now directly owns 73,039 shares of the company’s stock, valued at approximately $6,674,303.82. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Michael Burkes Brophy also recently made the following trade(s):

• On Tuesday, April 2nd, Michael Burkes Brophy sold 1,378 shares of Natera stock. The stock was sold at an average price of $92.62, for a total transaction of $127,630.36.
• On Thursday, March 28th, Michael Burkes Brophy sold 914 shares of Natera stock. The stock was sold at an average price of $90.42, for a total transaction of $82,643.88.
• On Tuesday, March 5th, Michael Burkes Brophy sold 2,826 shares of Natera stock. The stock was sold at an average price of $88.36, for a total transaction of $249,705.36.
• On Tuesday, February 6th, Michael Burkes Brophy sold 34,029 shares of Natera stock. The stock was sold at an average price of $70.03, for a total transaction of $2,383,050.87.
• On Thursday, February 1st, Michael Burkes Brophy sold 22,281 shares of Natera stock. The stock was sold at an average price of $67.73, for a total transaction of $1,509,092.13.
• On Monday, January 29th, Michael Burkes Brophy sold 3,235 shares of Natera stock. The stock was sold at an average price of $65.09, for a total transaction of $210,566.15.

Natera Stock Down 0.2 %

Shares of NTRA opened at $91.28 on Friday. The firm has a market cap of $11.02 billion, a P/E ratio of -24.08 and a beta of 1.37. Natera, Inc. has a 12-month low of $36.90 and a 12-month high of $98.82. The company’s 50-day moving average price is $87.29 and its 200 day moving average price is $67.00. The company has a current ratio of 4.10, a quick ratio of 3.96 and a debt-to-equity ratio of 0.37.

Natera (NASDAQ:NTRA) last issued its quarterly earnings data on Wednesday, February 28th. The medical research company reported ($0.64) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.73) by $0.09. The firm had revenue of $311.11 million for the quarter, compared to analyst estimates of $300.38 million. Natera had a negative net margin of 40.16% and a negative return on equity of 62.19%. On average, sell-side analysts forecast that Natera, Inc. will post -2.35 earnings per share for the current year.

Institutional Trading of Natera

Institutional investors and hedge funds have recently bought and sold shares of the business. RiverPark Advisors LLC purchased a new stake in Natera during the fourth quarter worth about $27,000. Principal Securities Inc. purchased a new stake in Natera during the fourth quarter worth about $32,000. Arcadia Investment Management Corp MI increased its stake in Natera by 47.8% during the first quarter. Arcadia Investment Management Corp MI now owns 538 shares of the medical research company’s stock worth $49,000 after purchasing an additional 174 shares during the period. Oliver Lagore Vanvalin Investment Group increased its stake in Natera by 109.3% during the fourth quarter. Oliver Lagore Vanvalin Investment Group now owns 745 shares of the medical research company’s stock worth $47,000 after purchasing an additional 389 shares during the period. Finally, Harvest Fund Management Co. Ltd purchased a new stake in shares of Natera during the third quarter worth approximately $44,000. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages have issued reports on NTRA. BTIG Research lifted their target price on shares of Natera from $75.00 to $85.00 and gave the stock a “buy” rating in a research note on Friday, December 29th. Stephens reissued an “overweight” rating and set a $78.00 price target on shares of Natera in a research report on Tuesday, January 30th. Piper Sandler boosted their price target on shares of Natera from $70.00 to $110.00 and gave the company an “overweight” rating in a research report on Wednesday, March 6th. Sanford C. Bernstein raised shares of Natera from a “market perform” rating to an “outperform” rating and set a $120.00 price target on the stock in a research report on Friday, April 5th. Finally, Craig Hallum began coverage on shares of Natera in a research report on Monday, April 8th. They set a “buy” rating and a $117.00 price target on the stock. One equities research analyst has rated the stock with a sell rating and fourteen have assigned a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $86.40.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.